CrossrefInfokarte
160 | VERLen: TAFASITAMAB, LENALINOMIDE, PLUS RITUXIMAB IN FRONTLINE DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS OVER 80 Y/O OR OLDER, A LYSA PHASE 2 TRIAL
Hematological Oncology · 2025-06 · 43 (S3)
DOI: 10.1002/hon.70093_160 ↗Abstract
Kein Abstract verfügbar.
EUVIMED